natgillin/translations-raw huggingface dataset:
Treatment with Cyramza may need to be stopped temporarily until high blood pressure is controlled with medicines, or stopped permanently if it cannot be adequately controlled.
Zdravljenje z zdravilom Cyramza bo morda treba začasno prekiniti, dokler visok krvni tlak ne bo uravnan z zdravili, ali pa trajno prekiniti, če krvnega tlaka ne bo mogoče zadovoljivo uravnati.
Treatment with Cystadane should be supervised by a doctor who has experience in the treatment of patients with homocystinuria.
Zdravljenje z zdravilom Cystadane mora nadzirati zdravnik z izkušnjami z zdravljenjem bolnikov s homocistinurijo.
Treatment with daily application should continue for two weeks.
Zdravljenje z vsakodnevnim nanašanjem se mora nadaljevati dva tedna.
Treatment with dasatinib is associated with anaemia, neutropaenia and thrombocytopaenia.
Zdravljenje z dasatinibom je povezano z anemijo, nevtropenijo in trombocitopenijo.
Treatment with desirudin is then continued twice daily post-operatively for 9 days up to a maximum of 12 days or until the patient is fully ambulant, whichever occurs first.
Zdravljenje z desirudinom se po operaciji nadaljuje dvakrat na dan od 9 do največ 12 dni oz. dokler bolnik ni popolnoma pokreten, kar se pač zgodi prej.
Treatment with desloratadine also significantly reduced interference with sleep and daytime function, as measured by a four-point scale used to assess these variables.
Zdravljenje z desloratadinom je tudi bistveno zmanjšalo motnje spanja in delovanje čez dan, kot so ugotovili z uporabo štiritočkovne lestvice za oceno teh spremenljivk.
Treatment with dronedarone should be stopped during the course of treatment, in case the patient develops any of the conditions which would lead to a contraindication as mentioned in section 4.3. Monitoring of co-administered medicinal products like digoxin and anti-coagulants is necessary.
Zdravljenje z dronedaronom je treba v teku zdravljenja ustaviti, če se bolniku pojavi kakšno stanje, ki bi povzročilo kontraindikacijo, kot je navedeno v poglavju 4.3. Potrebne so kontrole sočasno uporabljanih zdravil, npr. digoksina in antikoagulansov.
Treatment with duloxetine showed a statistically significantly greater improvement in GAD symptoms, as measured by PARS severity score for GAD (mean difference between duloxetine and placebo of 2.7 points [95% CI 1.3-4.0]), after 10 weeks of treatment.
Zdravljenje z duloksetinom je pokazalo statistično pomembnejše veliko izboljšanje simptomov generalizirane anksiozne motnje, merjeno z lestvico PARS izraženosti simptomov generalizirane anksiozne motnje (povprečna razlika med duloksetinom in placebom je znašala 2,7 točke [95% IZ 1,3- 4,0]), po 10 tednih zdravljenja.
Treatment with DUTREBIS should be stopped immediately if clinical signs, symptoms or laboratory abnormalities suggestive of pancreatitis occur.
Če se pojavijo klinični znaki, simptomi ali laboratorijske nepravilnosti, ki nakazujejo pankreatitis, je treba zdravljenje z zdravilom DUTREBIS nemudoma prekiniti.
Treatment with Dynepo should be initiated by physicians experienced in the treatment of anaemia associated with CRF.
Zdravljenje z Dynepom mora začeti zdravnik, ki ima izkušnje z zdravljenjem anemije, ki je povezana s kronično ledvično odpovedjo.
Treatment with Dynepo should be initiated by physicians experienced in the treatment of anaemia associated with CRF..
Zdravljenje z Dynepom mora začeti zdravnik, ki ima izkušnje z zdravljenjem anemije, ki je povezana s kronično ledvično odpovedjo.
Treatment with Econor at two different doses (20 and 35 mg valnemulin per kg of feed) for 21 days, started immediately after an outbreak of ERE, and was compared with no treatment.
21-dnevno zdravljenje z dvema različnima odmerkoma zdravila Econor (20 in 35 mg valnemulina na kg krme) so uvedli takoj po izbruhu epizootične enteropatije in ga primerjali z nezdravljenjem.
Treatment with efavirenz in combination with amprenavir and saquinavir is not recommended as the exposure to both protease inhibitors would be decreased.
Zdravljenje z efavirenzom v kombinaciji z amprenavirjem in s sakvinavirjem ni priporočljivo, ker bo izpostava obema zaviralcema proteaz zmanjšana.
Treatment with Elonva should be started under the supervision of a doctor experienced in treating fertility problems.
Zdravljenje z zdravilom Elonva je treba začeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem neplodnosti.
Treatment with Elonva was as effective as treatment with follitropin beta.
Zdravljenje z zdravilom Elonva je bilo enako učinkovito kot zdravljenje s folitropinom beta.
Treatment with eltrombopag should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after four weeks of eltrombopag therapy at 75 mg once daily.
Če se število trombocitov po štirih tednih zdravljenja z eltrombopagom v odmerku 75 mg enkrat na dan ne poveča do vrednosti, ki zadostujejo za preprečitev klinično pomembne krvavitve, je treba zdravljenje z eltrombopagom prekiniti.
Treatment with empagliflozin as add-on to metformin or metformin and a sulphonylurea resulted in a clinically meaningful reduction of 2-hour post-prandial glucose (meal tolerance test) at 24 weeks (add-on to metformin: placebo +5.9 mg/dl, empagliflozin 10 mg: -46.0 mg/dl, empagliflozin
Zdravljenje z empagliflozinom kot dodatno zdravljenje k metforminu ali metforminu in sulfonilsečnini je povzročilo klinično pomembno zmanjšanje vrednosti glukoze 2 uri po jedi (tolerančni test po jedi) pri 24. tednih (dodatno zdravljenje k metforminu: placebo +5,9 mg/dl, empagliflozin
Treatment with empagliflozin as add-on to metformin or metformin plus sulfonylurea resulted in clinically meaningful improvement of 2-hour post-prandial glucose (meal tolerance test) at 24 weeks (add-on to metformin, placebo: +5.9 mg/dl, empagliflozin 10 mg: -46.0 mg/dl, empagliflozin
Zdravljenje z empagliflozinom kot dodatno zdravljenje k metforminu ali metforminu s sulfonilsečnino je povzročilo klinično pomembno izboljšanje vrednosti glukoze 2 uri po jedi (tolerančni test po jedi) v
Treatment with empagliflozin in combination with metformin (5 mg and 500 mg; 5 mg and 1000 mg; 12.5 mg and 500 mg, and 12.5 mg and 1000 mg given twice daily) provided statistically significant improvements in HbA1c (Table 3) and led to greater reductions in FPG (compared to the individual components) and body weight (compared to metformin).
Zdravljenje z empagliflozinom v kombinaciji z metforminom (5 mg in 500 mg; 5 mg in 1000 mg; 12,5 mg in 500 mg ter 12,5 mg in 1000 mg dvakrat dnevno) je povzročilo statistično pomembno izboljšanje ravni HbA1c (Preglednica 3) in je vodilo v večje zmanjšanje vrednosti FPG (v primerjavi s posameznimi komponentami) ter telesne mase (v primerjavi z metforminom).
Treatment with empagliflozin led to a statistically significant reduction of HbA1c (Table 8) and clinically meaningful improvement in FPG compared to placebo at Week 24.
Zdravljenje z empagliflozinom je povzročilo statistično značilno zmanjšanje vrednosti HbA1c (preglednica 8) in klinično pomembno izboljšanje vrednosti FPG v primerjavi s placebom v 24. tednu.
Treatment with empagliflozin once daily resulted in statistically significant improvement in HbA1c, and 24 hour mean systolic and diastolic blood pressure as determined by ambulatory blood pressure monitoring (Table 7).
Zdravljenje z empagliflozinom enkrat na dan je povzročilo statistično značilno izboljšanje HbA1c in 24-urnega povprečnega sistoličnega in diastoličnega krvnega tlaka, kot je bilo ugotovljeno z ambulantnim spremljanjem krvnega tlaka (preglednica 7).
Treatment with empagliflozin once daily resulted in statistically significant improvement in HbA1c, and 24 hour mean systolic and diastolic blood pressure as determined by ambulatory blood pressure monitoring (Table 9).
Zdravljenje z empagliflozinom enkrat na dan je povzročilo statistično značilno izboljšanje HbA1c in 24-urnega povprečnega sistoličnega in diastoličnega krvnega tlaka, kot je bilo ugotovljeno z ambulantnim spremljanjem krvnega tlaka (preglednica 9).
Treatment with Emtriva should be initiated by a doctor who has experience in the treatment of HIV infection.
Zdravljenje z zdravilom Emtriva lahko uvede le zdravnik, ki ima izkušnje z zdravljenjem okužbe s HIV.
Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).
Zdravljenje z zdravilom Enbrel lahko sproži nastajanje avtoimunskih protiteles (glejte poglavje 4.8).
Treatment with Enbrel should not be initiated in patients with active infections including chronic or localised infections.
Zdravljenja z zdravilom Enbrel ne smete uvesti pri bolnikih z aktivnimi okužbami, vključno s kroničnimi ali lokaliziranimi okužbami.
Treatment with enoxaparin sodium is prescribed for a minimum of 6 days and continued until the return to full ambulation, for a maximum of 14 days.
Zdravljenje z natrijevim enoksaparinatom je treba predpisati vsaj za 6 dni in ga nadaljevati, dokler ni bolnik povsem mobilen, največ pa 14 dni.
Treatment with enoxaparin sodium may be prescribed for 8 days or carried out until hospital discharge, whichever comes first.
Zdravljenje z natrijevim enoksaparinatom se lahko predpiše za do odpusta iz bolnišnice ali največ osem dni (kar nastopi prej).
Treatment with enoxaparin sodium may be prescribed for 8 days or carried out until hospital discharge, whichever comes first.
Zdravljenje z natrijevim enoksaparinatom se lahko predpiše za osem dni ali do odpusta iz bolnišnice (kar nastopi prej).
Treatment with enoxaparin sodium must be discontinue d.
Zdravljenje z natrijevim enoksaparinatom je treba prekiniti.
Treatment with enoxaparin sodium must be discontinued.
Zdravljenje z natrijevim enoksaparinatom je treba prekiniti.
Treatment with Entyvio is the same for ulcerative colitis and Crohn’s disease.
Zdravljenje ulceroznega kolitisa in Crohnove bolezni z zdravilom Entyvio je enako.
Treatment with enzalutamide decreased the risk of FACT-P degradation by 37.5% compared with placebo (p < 0.001).
Zdravljenje z enzalutamidom je zmanjšalo tveganje upada skupne ocene FACT-P za 37,5 % v primerjavi s placebom (p < 0,001).
Treatment with Epclusa for 12 weeks demonstrated the statistical superiority (p < 0.001) compared to treatment with SOF+RBV for 24 weeks (treatment difference +14.8%; 95% confidence interval:
12-tedensko zdravljenje z zdravilom Epclusa se je pokazalo kot statistično boljše (p < 0,001) od 24- tedenskega zdravljenja s SOF + RBV (razlika v zdravljenju +14,8 %, 95-odstotni interval zaupanja:
Treatment with Epclusa in accordance with the recommended posology (see section 4.2) should be guided by an assessment of the potential benefits and risks for the individual patient.
Zdravljenje z zdravilom Epclusa v skladu s priporočenim odmerjanjem (glejte poglavje 4.2.) mora temeljiti na oceni možnih koristi in tveganj pri posameznem bolniku.
Treatment with Eperzan resulted in a mean weight loss for Eperzan (-0.7 kg) compared to a mean weight gain for insulin lispro (+0.8 kg) and the difference between treatment groups was statistically significant (see Table 6).
Zdravljenje z zdravilom Eperzan je v povprečju povzročilo zmanjšanje telesne mase z zdravilom Eperzan (- 0,7 kg), medtem ko se je z insulinom lispro telesna masa v povprečju povečala (+0,8 kg); razlika med terapevtskima skupinama je bila statistično značilna (glejte preglednico 6).
Treatment with Epoetin alfa HEXAL has to be initiated under the supervision of physicians experienced in the management of patients with the above indications.
Zdravljenje z zdravilom Epoetin alfa HEXAL je treba začeti pod nadzorom zdravnika, ki ima izkušnje z obravnavo bolnikov z zgoraj navedenimi indikacijami.
Treatment with Epoetin alfa HEXAL is divided into two stages – correction and maintenance phase.
Zdravljenje z zdravilom Epoetin alfa HEXAL poteka v dveh fazah – korekcijska in vzdrževalna faza.
Treatment with Epoetin Alfa Hexal must be started under the supervision of a doctor who has experience in the management of patients with the conditions that the medicine is used for.
Zdravljenje z zdravilom Epoetin Alfa Hexal se lahko uvede le pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem bolnikov, katerih bolezenska stanja se zdravijo s tem zdravilom.
Treatment with Eporatio is divided into two stages:
Zdravljenje z zdravilom Eporatio poteka v dveh fazah.
Treatment with Esbriet should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of IPF.
Zdravljenje z zdravilom Esbriet lahko uvede in nadzoruje le zdravnik specialist z izkušnjami pri diagnosticiranju in zdravljenju idiopatske pljučne fibroze.
Treatment with Esbriet should be started and supervised by a doctor experienced in the diagnosis and treatment of IPF.
Zdravljenje z zdravilom Esbriet lahko uvede in nadzoruje le zdravnik z izkušnjami z diagnosticiranjem in zdravljenjem idiopatske pljučne fibroze.
Treatment with Esmya usually leads to a significant reduction or may even stop your menstrual bleeding (your ‘period’) within the first 10 days of treatment.
Zdravljenje z zdravilom Esmya ponavadi v prvih 10 dneh zdravljenja bistveno zmanjša menstrualne krvavitve (mesečno perilo) ali jih lahko celo ustavi.
Treatment with esomeprazole 20 mg qd had no effect on the exposure of amprenavir (with and without concomitant ritonavir).
Zdravljenje z 20 mg esomeprazola enkrat na dan ni vplivalo na izpostavljenost amprenavirju (sočasno z ritonavirjem ali brez njega).
Treatment with EVRA should begin on the first day of withdrawal bleeding.
1. cikel kontracepcije z obližem EVRA mora ženska začeti na dan, ko se pojavi prekinitvena krvavitev.
Treatment with Exelon should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer’s disease or dementia in patients with Parkinson’s disease.
Zdravljenje z zdravilom Exelon mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem Alzheimerjeve bolezni ali demence pri bolnikih s Parkinsonovo boleznijo.
Treatment with Exjade should be started and supervised by a doctor who is experienced in the treatment of chronic iron overload.
Zdravljenje z zdravilom Exjade mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem kronične preobremenitve z železom.
Treatment with Fampyra should be prescribed and supervised by a doctor experienced in MS.
Zdravljenje z zdravilom Fampyra mora predpisati in nadzorovati zdravnik z izkušnjami pri obvladovanju MS.
Treatment with febuxostat in patients with ischaemic heart disease or congestive heart failure is not recommended.
Zdravljenje bolnikov z ishemično boleznijo srca ali kongestivnim srčnim popuščanjem s febuksostatom ni priporočljivo (glejte poglavje 4.8).
Treatment with febuxostat in patients with ischaemic heart disease or congestive heart failure is not recommended.
Zdravljenje bolnikov z ishemično boleznijo srca ali kongestivnim srčnim popuščanjem s febuksostatom ni priporočljivo.
Treatment with Fertavid and hCG should be continued for at least 3 to months before any improvement in spermatogenesis can be expected.
Zdravljenje z zdravilom Fertavid in hCG mora trajati najmanj 3 do 4 mesece, preden lahko pričakujete izboljšanje spermatogeneze.
Treatment with Fexeric may lead to elevations in iron stores, particularly in patients receiving concomitant intravenous iron therapy.
Zdravljenje z zdravilom Fexeric lahko povzroči povečanje zalog železa, predvsem pri bolnikih, ki sočasno prejemajo intravensko zdravljenje z železom.
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medicinal products.
Zaradi mielosupresivnih zdravil zdravljenje samo s filgrastimom ne zadostuje za preprečevanje trombocitopenije in anemije.
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medicinal products.
Zdravljenje s filgrastimom samim ne prepreči trombocitopenije in anemije, povzročenih z mielosupresivnimi zdravili.
Treatment with fondaparinux was demonstrated to be non-inferior to enoxaparin (VTE rates 3.9% and 4.1%, respectively).
Dokazali so, da zdravljenje s fondaparinuksom ni bilo slabše od enoksaparina (pogostosti VTE 3,9 % oziroma 4,1
Treatment with Gazyvaro is given in six cycles and each cycle lasts 28 days.
Zdravljenje z zdravilom Gazyvaro se daje v šestih ciklih, od katerih vsak traja 28 dni.
Treatment with Gilenya should be started and supervised by a physician experienced in MS.
Zdravljenje mora začeti in nadzorovati zdravnik z izkušnjami z multiplo sklerozo.
Treatment with Gilenya should not be initiated in patients receiving beta blockers, or other substances which may decrease heart rate, such as class Ia and III antiarrhythmics, calcium channel blockers (such as ivabradine, verapamil or diltiazem), digoxin, anticholinesteratic agents or pilocarpine because of the potential additive effects on heart rate (see sections 4.4 and 4.8).
Pri bolnikih, ki prejemajo zaviralce adrenergičnih receptorjev beta ali druga zdravila, ki lahko znižajo srčno frekvenco, na primer antiaritmike razredov Ia in III, zaviralce kalcijevih kanalčkov (kot so ivabradin, verapamil ali diltiazem), digoksin, zaviralci holinesteraze ali pilokarpin, naj se zdravljenja z zdravilom Gilenya ne uvaja zaradi možnosti aditivnega delovanja na srčno frekvenco (glejte poglavji 4.4 in 4.8).
Treatment with Glybera does not eliminate attacks of acute pancreatitis.
Zdravljenje z zdravilom Glybera ne odpravi napadov akutnega pankreatitisa.
Treatment with growth factors
Zdravljenje z rastnimi faktorji
Treatment with HEMANGIOL should be initiated by physicians who have expertise in the diagnosis, treatment and management of infantile haemangioma, in a controlled clinical setting where adequate facilities for handling of adverse reactions, including those requiring urgent measures, are available.
Zdravljenje z zdravilom HEMANGIOL smejo uvesti zdravniki, ki so izkušeni pri diagnosticiranju, zdravljenju in oskrbi infantilnega hemangioma, v nadzorovanem bolnišničnem okolju, kjer je na voljo dovolj ustrezne opreme za obravnavo neželenih reakcij, vključno s tistimi, ki zahtevajo takojšnje ukrepanje.
Treatment with Hepsera should be started by a doctor who has experience in the management of chronic hepatitis B. The recommended dose is 10 mg once a day.
Zdravljenje z zdravilom Hepsera mora uvesti zdravnik, ki ima izkušnje z zdravljenjem kroničnega hepatitisa B. Priporočeni odmerek je ena 10-miligramska tableta enkrat na dan.
Treatment with Hizentra should be started by a doctor or nurse who is experienced in the treatment of patients with weakened immune systems, but patients (or their carers) may administer it themselves once they have been trained and initially monitored.
Zdravljenje z zdravilom Hizentra uvede zdravnik ali medicinska sestra, ki ima izkušnje z zdravljenjem bolnikov z oslabljenim imunskim sistemom, vendar si lahko bolniki (ali njihovi negovalci) po ustreznem usposabljanju in začetnem spremljanju zdravilo dajejo tudi sami.
Treatment with Humira 40 mg every week significantly reduced the risk of worsening of abscesses and draining fistulas.
Zdravljenje z zdravilom Humira 40 mg vsak teden statistično zmanjša tveganje za poslabšanje abscesov in fistul z izcedkom.
Treatment with Humira must be started and supervised by a doctor who has experience in the treatment of the diseases that Humira is used to treat.
Zdravljenje z zdravilom Humira lahko uvede in nadzira le zdravnik, ki ima izkušnje z zdravljenjem bolezni, za katere se to zdravilo uporablja.
Treatment with Humira should not be initiated in patients with active infections including chronic or localized infections until infections are controlled.
Zdravljenja z zdravilom Humira se ne sme začeti pri bolnikih z aktivnimi okužbami, vključno s kroničnimi ali lokaliziranimi, dokler te niso obvladane.
Treatment with Ilaris induced a reduction of pain and reduced the risk of subsequent attacks in patients using ULT and unable to use both NSAIDs and colchicine, although the observed treatment difference compared to triamcinolone acetonide was less pronounced than with the overall study population.
Zdravljenje z zdravilom Ilaris je olajšalo bolečine in zmanjšalo tveganje za nadaljnje napade pri bolnikih, ki so uporabljali zdravila za zmanjševanje količine urata, niso pa mogli uporabljati niti nesteroidnih protivnetnih zdravil niti kolhicina, vendar je bila pri njih razlika v primerjavi z uporabo triamcinolon acetonida manj izrazita kot pri celotni študijski populaciji.
Treatment with Ilaris resulted in clinically relevant improvements in patients’ physical function and quality of life.
Zdravljenje z zdravilom Ilaris je omogočilo klinično pomembno izboljšanje telesnih funkcij in kakovosti življenja bolnikov.
Treatment with Ilaris should not be initiated in patients with neutropenia or leukopenia.
Pri bolnikih z nevtropenijo ali levkopenijo ne smemo uvesti zdravljenja z zdravilom Ilaris.
Treatment with imiquimod cream can be resumed after the skin reaction has moderated.
Ko se reakcija na koži umiri, se lahko zdravljenje z imikvimod kremo nadaljuje.
Treatment with imiquimod cream can be resumed after the skin reaction has moderated.
Zdravljenje se lahko nadaljuje potem, ko se reakcija na koži umiri.
Treatment with Imnovid may need to be interrupted or stopped, or the dose reduced, if the disease gets worse or the patient experiences certain side effects.
Zdravljenje z zdravilom Imnovid je po potrebi treba prekiniti ali ustaviti ali pa je treba zmanjšati odmerek, če se bolezen poslabša ali če se pri bolniku pojavijo nekateri neželeni učinki.
Treatment with Imnovid must be started and supervised by a doctor experienced in treating multiple myeloma.
Zdravljenje z zdravilom Imnovid mora začeti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem multiplega mieloma.
Treatment with INCIVO should be initiated and monitored by a physician experienced in the management of chronic hepatitis C.
Zdravljenje z zdravilom INCIVO naj uvede in spremlja zdravnik z izkušnjami pri zdravljenju kroničnega hepatitisa C.
Treatment with Incivo should be started and monitored by a doctor experienced in managing chronic hepatitis C infections.
Zdravljenje z zdravilom Incivo naj uvede in spremlja zdravnik z izkušnjami pri zdravljenju okužb s kroničnim hepatitisom C.
Treatment with INCRELEX is a long-term therapy.
Zdravilo INCRELEX je namenjeno dolgotrajnemu zdravljenju.
Treatment with INCRELEX should be directed by physicians who are experienced in the diagnosis and management of patients with growth disorders.
Zdravljenje z zdravilom INCRELEX mora voditi zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem bolnikov z motnjami rasti.
Treatment with Incruse 55 mcg
Zdravljenje z zdravilom Incruse 55 µg
Treatment with indinavir alone or in combination with other antiretroviral agents (i.e., nucleoside analogues) has so far been documented to reduce viral load and increase CD4 lymphocytes in patients with CD4 cell counts below 500 cells/mm3.
Doslej so ugotovili, da zdravljenje z indinavirjem samim ali v kombinaciji z drugimi protiretrovirusnimi zdravili (npr. nukleozidnimi analogi) zmanjša virusno obremenitev in poveča število CD4 limfocitov pri bolnikih s številom CD4 celic, manjšim od 500 celic/mm3.
treatment with indinavir.
zdravljenju z indinavirjem, je bila
Treatment with inhaled nitric oxide might aggravate cardiac insufficiency in a situation with left-to- right shunting.
V primeru obvoda krvnega obtoka z leve na desno lahko zdravljenje z vdihovanjem dušikovega oksida poslabša srčno insuficienco.
Treatment with Inovelon should be started by a paediatrician (a doctor specialised in treating children) or a neurologist (a doctor who treats brain disorders).
Zdravljenje z zdravilom Inovelon mora uvesti pediater (zdravnik, ki je specializiran za zdravljenje otrok) ali nevrolog (zdravnik, ki zdravi možganske bolezni).
Treatment with Instanyl should be started by and remain under the supervision of a doctor who has experience in the management of opioid treatment in cancer patients.
Zdravljenje z zdravilom Instanyl sme uvesti in ves čas voditi le zdravnik, ki ima izkušnje z izvajanjem zdravljenja z opiodi pri bolnikih z rakom.